These findings highlight the unmet medical need and provide an important benchmark for studies that address this refractory
patient population.
M2 EQUITYBITES-April 30, 2014-Cell Therapeutics introduces PIXUVRI for treating adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, reflecting its first and only approved monotherapy in the EU for this
patient populationAssuming 300 (15 percent) of the 2,000 patients in an internal medicine practice are Medicare patients, and the complex diabetic and CHF population targeted for the chronic care improvement pilot program constitutes 10 percent of that
patient population (1.5 percent of the total practice), there should be 30 patients in the practice who--if they comply with evidence-based protocols--would produce a savings of (30 X $850=) $25,500 per year.
The low-risk
patient population is the final surgical risk category to be approved for this minimally invasive alternative to open-heart surgical valve replacement and includes patients who may be younger and more active than higher-risk patients, the company stated.
ENPNewswire-August 7, 2019--MorphoSys Discloses Biomarker to Stratify
Patient Population in B-MIND Study of Tafasitamab plus Bendamustine in r/r DLBCL
Enrollment and treatment of the GT3
patient population was completed later, therefore the analysis of this population is ongoing.
Asthma is a common chronic condition that has long plagued the pediatric
patient population. Asthma in children can cause excessive school absenteeism, hospitalizations, and even death.
In addition, available literature revealed a lack of established pathways or protocols to mobilize this unique
patient population. Our goal was both to formalize the practice through a standard protocol with built-in safety mechanisms and to disseminate our findings to permit safe mobilization of this
patient population.
We hypothesized that olfactory dysfunction may be present in this
patient population. We aimed to investigate olfactory dysfunction in patients with BTM and to determine etiologic factors.
The company said it plans to conduct a phase 2 study in patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, a
patient population where Tecentriq has accelerated approval in the US.
Although these patients made up only 20% of the
patient population, they required 50.4% of all available nursing care hours and dollars.